References

Targeted therapies: a new generation of cancer treatments

2008 · External reference

A new initiative on precision medicine

10.1056/nejmp1500523 · 2015 · External reference

Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease

10.1093/eurheartj/eht114 · 2013 · External reference

Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors

10.1016/j.jacc.2015.07.025 · 2015 · External reference

Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia

2015 · External reference

Cancer statistics, 2016

2016 · External reference

Cancer treatment and survivorship statistics, 2014

2014 · External reference

Emerging paradigms in cardiomyopathies associated with cancer therapies

10.1161/circresaha.113.300218 · 2013 · External reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

10.1056/nejmoa062867 · 2006 · External reference

Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial

10.1200/jco.2014.32.15_suppl.7081 · 2014 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Preservation of contractile characteristics of human myocardium in multi-day cell culture

10.1006/jmcc.1999.0978 · 1999 · External reference

The human adult cardiomyocyte phenotype

10.1016/s0008-6363(03)00253-0 · 2003 · External reference

Long-term primary cultures of human adult atrial cardiac myocytes: cell viability, structural properties and BNP secretion in vitro

10.1016/j.ijcard.2007.10.058 · 2008 · External reference

Organotypic slice culture from human adult ventricular myocardium

10.1093/cvr/cvr259 · 2012 · External reference

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

10.1172/jci72931 · 2014 · External reference

A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity

10.1161/circresaha.111.255695 · 2011 · External reference

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

10.1016/j.taap.2009.12.032 · 2010 · External reference

How to isolate cardiac myocytes

10.1093/cvr/28.2.280 · 1994 · External reference

Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway

10.1124/jpet.106.108845 · 2006 · External reference

Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets

10.1007/s10565-008-9070-1 · 2009 · External reference

Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes

10.18632/aging.100203 · 2010 · External reference

Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress

10.1007/s11010-011-1194-6 · 2012 · External reference

Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells

10.1093/toxsci/kfn157 · 2008 · External reference

Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart

10.1161/01.res.69.6.1476 · 1991 · External reference

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

10.1161/01.cir.94.4.817 · 1996 · External reference

Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride

10.1152/ajpheart.1997.273.5.h2534 · 1997 · External reference

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

10.1016/s0008-6363(02)00846-5 · 2003 · External reference

Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends

10.1016/j.vascn.2005.07.003 · 2006 · External reference

Alfuzosin delays cardiac repolarization by a novel mechanism

10.1124/jpet.107.128405 · 2008 · External reference

Screening drug-induced arrhythmia using human induced pluripotent stem cell–derived cardiomyocytes and low-impedance microelectrode arrays

2013 · External reference

Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes

10.1172/jci200112131 · 2001 · External reference

Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells the matrix sandwich method

10.1161/circresaha.112.273144 · 2012 · External reference

Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling

10.1073/pnas.1200250109 · 2012 · External reference

Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions

10.1038/nprot.2012.150 · 2013 · External reference

Human stem cells for modeling heart disease and for drug discovery

10.1126/scitranslmed.3008921 · 2014 · External reference

Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes

10.1371/journal.pone.0003474 · 2008 · External reference

Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells

10.1111/j.1582-4934.2009.00996.x · 2011 · External reference

High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents

10.1152/ajpheart.00694.2011 · 2011 · External reference

Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories

10.1016/j.yjmcc.2015.05.003 · 2015 · External reference

Patient-specific induced pluripotent stem-cell models for long-QT syndrome

10.1056/nejmoa0908679 · 2010 · External reference

Cell size and communication: role in structural and electrical development and remodeling of the heart

10.1016/j.hrthm.2004.06.010 · 2004 · External reference

Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG

10.1016/j.yjmcc.2012.02.002 · 2012 · External reference

Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture

10.1253/circj.cj-12-0987 · 2013 · External reference

Induced pluripotent stem cells: at the heart of cardiovascular precision medicine

10.1038/nrcardio.2016.36 · 2016 · External reference

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

10.1200/jco.1997.15.4.1544 · 1997 · External reference

Racial disparities in treatment and survival among women with early-stage breast cancer

10.1200/jco.2005.12.633 · 2005 · External reference

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

10.1200/jco.2006.06.5961 · 2006 · External reference

In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes

10.1089/scd.2007.0280 · 2009 · External reference

Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes

10.1016/j.scr.2009.11.004 · 2010 · External reference

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease specific patterns of cardiotoxicity

10.1161/circulationaha.113.001883 · 2013 · External reference

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes

10.1016/j.taap.2013.04.027 · 2013 · External reference

Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell derived cardiomyocytes

10.1093/toxsci/kfr158 · 2011 · External reference

Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model

10.1093/toxsci/kft205 · 2013 · External reference

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity

10.1038/nm.4087 · 2016 · External reference

What is the point of large-scale collections of human induced pluripotent stem cells?

10.1038/nbt.2710 · 2013 · External reference

Multiplex genome engineering using CRISPR/Cas systems

10.1126/science.1231143 · 2013 · External reference

Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity

1998 · External reference

Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats

10.1016/0041-008x(85)90284-4 · 1985 · External reference

Sexual dimorphism of doxorubicin-mediated cardiotoxicity potential role of energy metabolism remodeling

10.1161/circheartfailure.114.001180 · 2015 · External reference

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

10.1038/sj.bjc.6690761 · 1999 · External reference

The cancer research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies

10.1016/j.ejca.2003.12.020 · 2004 · External reference

Multi-species toxicology approaches for oncology drugs: the US perspective

10.1016/j.ejca.2003.11.024 · 2004 · External reference

Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response

10.1126/science.877547 · 1977 · External reference

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

10.1038/nm.2919 · 2012 · External reference

p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice

10.1126/scisignal.2002918 · 2012 · External reference

ErbB2 is essential in the prevention of dilated cardiomyopathy

10.1038/nm0502-459 · 2002 · External reference

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib

10.1200/jco.2010.34.4309 · 2011 · External reference

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase

10.1111/j.1752-8062.2008.00090.x · 2009 · External reference

A genetic screen for mutations affecting embryogenesis in zebrafish

10.1242/dev.123.1.37 · 1996 · External reference

The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio

10.1242/dev.123.1.1 · 1996 · External reference

Transparent adult zebrafish as a tool for in vivo transplantation analysis

10.1016/j.stem.2007.11.002 · 2008 · External reference

Defective “pacemaker” current (Ih) in a zebrafish mutant with a slow heart rate

10.1073/pnas.94.9.4554 · 1997 · External reference

Drugs that induce repolarization abnormalities cause bradycardia in zebrafish

10.1161/01.cir.0000061912.88753.87 · 2003 · External reference

Zebrafish: a new model on the pharmaceutical catwalk

10.1002/bies.10326 · 2003 · External reference

Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase

10.1126/scitranslmed.3010189 · 2014 · External reference

Predictive in silico modeling for hERG channel blockers

10.1016/s1359-6446(04)03278-7 · 2005 · External reference

Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation

10.1371/journal.pcbi.1002061 · 2011 · External reference

MICE models: superior to the HERG model in predicting Torsade de Pointes

10.1038/srep02100 · 2013 · External reference

Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk

10.1093/cvr/cvr044 · 2011 · External reference

Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium

10.1016/j.ahj.2013.11.004 · 2014 · External reference

Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study

10.1200/jco.2001.19.13.3163 · 2001 · External reference

Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level

10.1016/j.jacc.2015.04.059 · 2015 · External reference

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review

10.1093/annonc/mdf167 · 2002 · External reference

Congestive heart failure in patients treated with doxorubicin

10.1002/cncr.11407 · 2003 · External reference

Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings

10.1200/jco.2008.21.1953 · 2009 · External reference

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

10.1186/1471-2407-10-337 · 2010 · External reference

Trastuzumab containing regimens for early breast cancer

2012 · External reference

Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study

2014 · External reference

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review

10.1016/j.jacc.2014.01.073 · 2014 · External reference

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children

2011 · External reference

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children

10.1002/pbc.24505 · 2013 · External reference

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

10.1038/ng.3374 · 2015 · External reference

Integrating electronic health record genotype and phenotype datasets to transform patient care

10.1002/cpt.321 · 2016 · External reference

Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data

10.1038/nbt.2749 · 2013 · External reference

Phenome-wide association studies as a tool to advance precision medicine

10.1146/annurev-genom-090314-024956 · 2016 · External reference

Reversible cardiomyopathy associated with sunitinib and sorafenib

10.1056/nejmc1108849 · 2011 · External reference

Unresolved reference

External reference